Work

Figure 1 from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study

Year: 2026

Type: other

Abstract: Plasma sample processing flow chart. FMI, Foundation Medicine, Inc.; QC, quality control; SEQ, sequencing; TSO500, TruSight Oncology 500 ctDNA Assay. aUW OncoPlex NGS assay. bcobas BRAF V600E PCR assay. cBanked plasma samples were selected based on a TSO500-negative result for BRAF V600E and were previously tested with F1LCDx.

DOI: 10.1158/2767-9764.33110908

Authors: Gregory J. Riely, Jean-François Martini, Norberto Pantoja Galicia, Brian Tunquist, Keith Wilner, Richard S.P. Huang, Cui Guo, Shibing Deng, Wei Meng, Jimmy Kiely, Linda Zhou, David L. Smith, Mark Hartman, Chenming Cui, Nada Rifi, Bruce E. Johnson, Anne S. Tsao

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W7171686040

Cites:

Cited by:

Related to: 10